NASDAQ | ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology.
The fund is non-diversified.
Top 20 Holdings
Asset | Name | Sector | Industry | Weight |
---|---|---|---|---|
LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 5.44% |
RHHBY | Roche Holding Ltd ADR | Healthcare | Drug Manufacturers - General | 5.30% |
RVMD | Revolution Medicines Inc | Healthcare | Biotechnology | 5.10% |
BMY | Bristol-Myers Squibb Company | Healthcare | Drug Manufacturers - General | 4.72% |
AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 4.56% |
NOVN | Novartis AG | Healthcare | Drug Manufacturers - General | 4.32% |
EXEL | Exelixis Inc | Healthcare | Biotechnology | 4.18% |
BBIO | BridgeBio Pharma Inc | Healthcare | Biotechnology | 4.08% |
ZLAB | Zai Lab Ltd | Healthcare | Biotechnology | 3.85% |
NUVL | Nuvalent Inc | Healthcare | Biotechnology | 3.69% |
4568 | Daiichi Sankyo Co. Ltd. | Healthcare | Drug Manufacturers - General | 3.23% |
BGNE | BeiGene Ltd | Healthcare | Biotechnology | 3.08% |
GMAB | Genmab AS | Healthcare | Biotechnology | 3.08% |
AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 3.04% |
IMGN | ImmunoGen Inc | Healthcare | Biotechnology | 3.00% |
SMMT | Summit Therapeutics PLC | Healthcare | Biotechnology | 2.96% |
MRK | Merck & Company Inc | Healthcare | Drug Manufacturers - General | 2.95% |
MRUS | Merus BV | Healthcare | Biotechnology | 2.90% |
BPMC | Blueprint Medicines Corp | Healthcare | Biotechnology | 2.89% |
ACLX | Arcellx Inc | Healthcare | Biotechnology | 2.77% |